Opinion

Video

Management of Recurrent C Difficile Infections in the Future

Key Takeaways

  • Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
  • Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
SHOW MORE

Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
1 expert in this video
1 expert in this video
Dr Mingyang Song
Casey Koch, PharmD, sitting for a video interview
1 expert in this video
1 expert in this video
Dr John Heymach
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo